Top View
- Black Lunula Caused by Tegafur
- Preliminary Results of Tranilast Treatment for Patients with Advanced Castration-Resistant Prostate Cancer
- Tegafur/Gimeracil/Oteracil 15Mg/4.35Mg/11.8Mg and 20Mg/5.8Mg/15.8Mg Hard Capsules (Teysuno®) SMC No
- Estramustine Phosphate Induces PC3 Apoptosis in Prostate Cancer Occurrence and Development
- Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor
- Uracil/Tegafur Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer: a Multi-Institutional Phase II Trial
- Orphan Drug Designation List
- Longitudinal Trends in Use and Costs of Targeted Therapies for Common Cancers in Taiwan: a Retrospective Observational Study
- List of Cancer Drugs (The First Batch) Ⅰ.Cancer Drugs
- Integrated Bioinformatics Analysis for the Screening of Hub Genes And
- Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea
- Inhibitors of the Menin-Mll Interaction Inhibitoren Der Menin-Mll-Interaktion Inhibiteurs De L’Interaction Ménine-Mll
- Uracil-Tegafur and Tamoxifen Vs Cyclophosphamide, Methotrexate
- Ethinylestradiol Improves Prostate-Specific Antigen Levels in Pretreated Castration-Resistant Prostate Cancer Patients
- A Single-Arm, Phase 2 Study of Adjuvant Chemotherapy with Oral
- Human Medicines Highlights 2020 Authorisation of New Medicines
- Adjuvant Immunochemotherapy with Oral Tegafur/Uracil Plus PSK in Patients with Stage II Or III Colorectal Cancer: a Randomised Controlled Study
- Phase II Study of Triplet Chemotherapy Using Tegafur-Uracil, Vinorelbine, Gemcitabine for Advanced Non-Small Cell Lung Cancer
- Capecitabine Therapy and DPYD Genotype
- Cytotoxic Chemotherapy As First-Line Therapy For
- Teysuno, Tegafur/Gimeracil/Oteracil
- High-Dose Oral Tegafur-Uracil Maintenance Therapy in Patients with Uterine Cervical Cancer
- 5-Fluorouraci Capecitabine and Tegafur Containing Products
- CHAPTER 16: USE of ANTINEOPLASTIC AGENTS INCLUDING ENDOCRINE THERAPY Malaysian Statistics on Medicines 2006
- A Fatal Myelosuppression, Diarrhea and Neurotoxicity Induced By
- Efficacy of Tegafur-Uracil in Advanced Urothelial Cancer Patients After the Treatment Failure of Platinum-Based Chemotherapy
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Retrospective Study of S-1 Versus Tegafur/Uracil and Oral Leucovorin
- NICE-Approved Drugs Outside Services Provided (May 2019)
- Supplements for Immune Enhancement in Hematologic Malignancies
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Medicines & Vaccines in Development for Cancer
- Pdf 471.32 K
- UFT Capsules (Uracil-Tegafur)
- Feasibility of Metronomic Chemotherapy with Tegafur-Uracil, Cisplatin, and Dexamethasone for Docetaxel-Refractory Prostate Cancer
- Real-World Utilization of Target- and Immunotherapies for Lung Cancer: a Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data
- Capecitabine and Tegafur with Uracil for the Treatment of Metastatic Colorectal Cancer: Systematic Review and Economic Evaluation
- Assessment Report for Teysuno (Tegafur/Gimeracil/Oteracil)
- Capecitabine and Tegafur with Uracil for Metastatic Colorectal Cancer
- Preclinical Evaluation of Oral Metronomic Topotecan
- Teysuno, INN- Tegafur/Gimeracil/Oteracil
- Renal Impairment Hepatic Impairment Agent PK Summary Available